Research Keyword: serotonin receptor agonism

Psychedelic Psilocybin-Assisted Therapy Reduces Depressive Symptoms in Adults with Cancer and Depression

mycolabadmin

Researchers conducted a trial testing psilocybin-assisted therapy in cancer patients with depression. Participants received a single dose of psilocybin combined with therapy sessions. After eight weeks, most patients showed significant improvement in depression symptoms, with many achieving full remission. The treatment was generally safe with only mild side effects, and patients reported feeling more hopeful and better equipped to cope with their cancer diagnosis.

Read More »

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

mycolabadmin

This comprehensive review explores how psychedelic drugs like psilocybin mushrooms, DMT, and LSD may offer new hope for treating depression, anxiety, and PTSD, especially for patients who don’t respond to conventional antidepressants. Historically used in spiritual ceremonies for thousands of years, these compounds are now being scientifically studied and show promise with fewer side effects than many traditional psychiatric medications. The authors emphasize that while results are encouraging, more research and regulatory approval are needed before these treatments become widely available in mainstream medicine.

Read More »

Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial

mycolabadmin

This study tests whether psilocybin (the active compound in certain mushrooms) can help people with obsessive-compulsive disorder who haven’t responded to standard treatments. In a carefully controlled trial, participants receive either a single dose of psilocybin or a placebo while receiving psychological support, with their brain activity and symptoms monitored. The research aims to determine if this novel treatment is safe and whether it could work faster than existing medications for this difficult-to-treat condition.

Read More »

Study protocol for ‘Psilocybin in patients with fibromyalgia: brain biomarkers of action’

mycolabadmin

Researchers are testing whether psilocybin (the active compound in magic mushrooms) combined with therapeutic support can help people with fibromyalgia, a chronic pain condition. The study will measure brain activity using EEG and brain imaging to understand how psilocybin might reduce pain and improve mental health. Twenty patients will receive guided psilocybin sessions over eight weeks while researchers track changes in brain function and pain levels.

Read More »

Exploring Psilocybe spp. mycelium and fruiting body chemistry for potential therapeutic compounds

mycolabadmin

This study compared the chemical makeup of psilocybin mushroom mycelium (the root-like growth) versus fruiting bodies (the mushrooms themselves) to understand their different therapeutic potential. While fruiting bodies contain much higher levels of psilocybin, the psychoactive compound, mycelium accumulates other beneficial compounds like α-GPC that may enhance cognition and motor function without strong psychedelic effects. This research suggests that mushroom mycelium could be developed as a non-intoxicating therapeutic alternative with its own unique health benefits.

Read More »

Scoping Review: The Role of Psychedelics in the Management of Chronic Pain

mycolabadmin

This review examines how psychedelic drugs like LSD and psilocybin might help treat chronic pain conditions such as cluster headaches and phantom limb pain. The researchers found nine studies suggesting these substances could reduce pain by affecting serotonin receptors in the brain. While early results are promising, more rigorous clinical trials are needed before these drugs can become standard pain treatments. The authors note that strict legal restrictions on psychedelics currently limit research opportunities.

Read More »
Scroll to Top